Institutional members access full text with Ovid®

Share this article on:

Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (rhPDGF-BB/β-TCP): An Alternative to Autogenous Bone Graft

DiGiovanni, Christopher W. MD; Lin, Sheldon S. MD; Baumhauer, Judith F. MD, MPH; Daniels, Timothy MD; Younger, Alastair MD; Glazebrook, Mark MD, PhD; Anderson, John MD; Anderson, Robert MD; Evangelista, Peter MD; Lynch, Samuel E. DMD, DMSc; the North American Orthopedic Foot and Ankle Study Group

Journal of Bone & Joint Surgery - American Volume: 3 July 2013 - Volume 95 - Issue 13 - p 1184–1192
doi: 10.2106/JBJS.K.01422
Scientific Articles
Supplementary Content

Background: Joint arthrodesis employing autogenous bone graft (autograft) remains a mainstay in the treatment of many foot and ankle problems. However, graft harvest can lead to perioperative morbidity and increased cost. We tested the hypothesis that purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) homodimer combined with an osteoconductive matrix (beta-tricalcium phosphate [β-TCP]) would be a safe and effective alternative to autograft.

Methods: A total of 434 patients were enrolled in thirty-seven clinical sites across North America in a prospective, randomized (2:1), controlled, non-inferiority clinical trial to compare the safety and efficacy of the combination rhPDGF-BB and β-TCP with those of autograft in patients requiring hindfoot or ankle arthrodesis. Radiographic, clinical, functional, and quality-of-life end points were assessed through fifty-two weeks postoperatively.

Results: Two hundred and sixty patients (394 joints) underwent arthrodesis with use of rhPDGF-BB/β-TCP. One hundred and thirty-seven patients (203 joints) underwent arthrodesis with use of autograft. With regard to the primary end point, 159 patients (61.2% [262 joints (66.5%)]) in the rhPDGF-BB/β-TCP group and eighty-five patients (62.0% [127 joints (62.6%)]) in the autograft group were fused as determined by computed tomography at six months (p < 0.05). Clinically, 224 patients (86.2%) [348 joints (88.3%)]) in the rhPDGF-BB/β-TCP group were considered healed at fifty-two weeks, compared with 120 patients (87.6% [177 joints (87.2%)] in the autograft group (p = 0.008). Overall, fourteen of sixteen secondary end points at twenty-four weeks and fifteen of sixteen secondary end points at fifty-two weeks demonstrated statistical non-inferiority between the groups, and patients in the rhPDGF-BB/β-TCP group were found to have less pain and an improved safety profile.

Conclusions: In patients requiring hindfoot or ankle arthrodesis, treatment with rhPDGF-BB/β-TCP resulted in comparable fusion rates, less pain, and fewer side effects as compared with treatment with autograft.

Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

1Department of Orthopaedic Surgery (C.W.D.) and the Department of Diagnostic Imaging (P.E.), The Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903. E-mail address for C.W. DiGiovanni:

2University of Medicine & Dentistry of New Jersey, 90 Bergen Street, Suite #7300, Newark, NJ 07101

3University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642

4St. Michael’s Hospital, 55 Queen Street East, Suite 800, Toronto, ON M5C 1R6, Canada

5St. Paul’s Hospital, Burrard Medical Centre, 1144 Burrard Street, Suite 560, Vancouver, BC V6Z 2A5, Canada

6Halifax Infirmary, 1796 Summer Street, Room 4867, Halifax, NS B3H 3A7, Canada

7Orthopaedic Associates of Michigan, PC, 1111 Leffingwell N.E., Suite 100, Grand Rapids, MI 49525

8OrthoCarolina Research Institute, Inc., 2001 Vail Avenue, Suite 250, Charlotte, NC 28207

9BioMimetic Therapeutics, Inc., 389 Nichol Mill Lane, Franklin, TN 37067

Copyright 2013 by The Journal of Bone and Joint Surgery, Incorporated
You currently do not have access to this article

To access this article: